Date: 2017-02-13
Type of information: Construction of new premises
Compound: viral vector production facility in Seneffe (Belgium)
Company: Novasep (France)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On February 13, 2017, Novasep announced that the company is investing in €27 million viral vector production facility. The new site, scheduled to be operational in early 2019, will be built at Novasep's facility in Seneffe, Belgium, to complement the existing lab-scale suites of the neighboring site in Gosselies. The site will feature two cGMP suites on 2000 sqm. equipped with a set of single-use bioreactors ranging from 200L up to 2000L. It will fit perfectly with the production requirements for phase III and commercial stages. The plant is a response to the strong market demand driven by both a growing interest in viral vector based therapies and a maturing clinical pipeline including gene therapies or immunotherapies and "new generation" therapeutic vaccines. With more than 300 products in clinical studies and 9 products launched, the market is expecting to see high single-digit growth over the five next years.
Financial terms:
Latest news:
